Close
Achema middle east
swop processing & packaging

Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Genentech, a member of the Roche group announced that new data from three Phase III studies of the investigational medicine OCREVUS™ (ocrelizumab) will be presented during the 68th American Academy of Neurology (AAN) annual meeting from April 15-21 in Vancouver, Canada.

In addition, results of a novel endpoint, No Evidence of Disease Activity (NEDA) will be presented from the Phase III studies in relapsing MS at the Clinical Trials Plenary Session on Wednesday, April 20. NEDA is a composite of key measures of disease activity that assesses level of disease control. Patients are considered to have achieved NEDA if they have no relapses, no disability progression and no new or enlarging MRI lesions over a specified time interval, for example, two years of a clinical trial.

“The data being presented at AAN show that ocrelizumab significantly reduced disability progression and brain tissue damage in both relapsing and primary progressive forms of MS,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The analyses demonstrate ocrelizumab’s consistent effect across important measures of disease activity and provide further insights into the clinical effect of ocrelizumab in people with MS.”

Latest stories

Related stories

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »